{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood&page=14",
    "query": {
      "intervention": "Blood",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 20635,
    "total_pages": 2064,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blood&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T02:50:40.518Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01226173",
      "title": "Dengue Virus NS1 Antigen (Bio-Rad) Clinical Protocol",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Mass Screening"
      ],
      "interventions": [
        {
          "name": "Bio-Rad Platelia Dengue NS1 Ag test",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Bio-Rad Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 182353,
      "start_date": "2010-03",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2012-09-24",
      "last_synced_at": "2026-10-21T02:50:40.518Z",
      "location_count": 1,
      "location_summary": "Lauderhill, Florida",
      "locations": [
        {
          "city": "Lauderhill",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01226173"
    },
    {
      "nct_id": "NCT01952054",
      "title": "Denosumab for Breast Cancer With Bone Mets",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Denosumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 7,
      "start_date": "2015-02-09",
      "completion_date": "2018-10-10",
      "has_results": true,
      "last_update_posted_date": "2019-11-22",
      "last_synced_at": "2026-10-21T02:50:40.518Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01952054"
    },
    {
      "nct_id": "NCT03288454",
      "title": "Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Ciraparantag",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Apixaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "50 Years to 75 Years"
      },
      "enrollment_count": 60,
      "start_date": "2017-08-30",
      "completion_date": "2019-08-05",
      "has_results": true,
      "last_update_posted_date": "2025-09-02",
      "last_synced_at": "2026-10-21T02:50:40.518Z",
      "location_count": 1,
      "location_summary": "Secaucus, New Jersey",
      "locations": [
        {
          "city": "Secaucus",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03288454"
    },
    {
      "nct_id": "NCT03927105",
      "title": "Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Peripheral T Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "cabiralizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2019-04-25",
      "completion_date": "2023-07-06",
      "has_results": true,
      "last_update_posted_date": "2026-05-07",
      "last_synced_at": "2026-10-21T02:50:40.518Z",
      "location_count": 3,
      "location_summary": "Ann Arbor, Michigan • Columbus, Ohio • Madison, Wisconsin",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03927105"
    },
    {
      "nct_id": "NCT02278822",
      "title": "Oral Liposomal Glutathione Supplementation in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Low dose oral liposomal glutathione supplementation",
          "type": "OTHER"
        },
        {
          "name": "High dose oral liposomal glutathione supplementation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "50 Years to 80 Years"
      },
      "enrollment_count": 12,
      "start_date": "2014-11",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2016-07-11",
      "last_synced_at": "2026-10-21T02:50:40.518Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02278822"
    },
    {
      "nct_id": "NCT00671931",
      "title": "Susceptibility of Motor-Evoked Potentials to Varying Targeted Blood Levels of Dexmedetomidine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Scoliosis"
      ],
      "interventions": [
        {
          "name": "low dexmedetomidine, low propofol",
          "type": "DRUG"
        },
        {
          "name": "high dexmedetomidine, low propofol",
          "type": "DRUG"
        },
        {
          "name": "Dexmedetomidine",
          "type": "DRUG"
        },
        {
          "name": "Dexmedetomidin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Hospital Medical Center, Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "10 Years to 25 Years"
      },
      "enrollment_count": 44,
      "start_date": "2007-04",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2013-08-23",
      "last_synced_at": "2026-10-21T02:50:40.518Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00671931"
    },
    {
      "nct_id": "NCT00231153",
      "title": "Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infection"
      ],
      "interventions": [
        {
          "name": "Omiganan 1% gel",
          "type": "DRUG"
        },
        {
          "name": "Povidone-Iodine 10%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cadence Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": 1859,
      "start_date": "2005-08",
      "completion_date": "2008-07",
      "has_results": true,
      "last_update_posted_date": "2009-08-13",
      "last_synced_at": "2026-10-21T02:50:40.518Z",
      "location_count": 36,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Arcadia, California + 33 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Arcadia",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00231153"
    },
    {
      "nct_id": "NCT01927237",
      "title": "Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Low Tidal Volume Ventilation",
        "Acute Respiratory Distress Syndrome"
      ],
      "interventions": [
        {
          "name": "HLR",
          "type": "OTHER"
        },
        {
          "name": "EHR",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 0,
      "start_date": "2013-09",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2017-02-27",
      "last_synced_at": "2026-10-21T02:50:40.518Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01927237"
    },
    {
      "nct_id": "NCT06413602",
      "title": "The Synergistic Effects of AIH and FES in Persons With MS",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Sclerosis",
        "Multiple Sclerosis, Relapsing-Remitting",
        "Multiple Sclerosis, Secondary Progressive"
      ],
      "interventions": [
        {
          "name": "Acute Intermittent Hypoxia",
          "type": "OTHER"
        },
        {
          "name": "Neuromuscular Electrical Stimulation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Shirley Ryan AbilityLab",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 40,
      "start_date": "2024-11-01",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-10-21T02:50:40.518Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06413602"
    },
    {
      "nct_id": "NCT00429572",
      "title": "Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Stem Cell Infusion",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 19,
      "start_date": "1998-01",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2012-08-07",
      "last_synced_at": "2026-10-21T02:50:40.518Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00429572"
    }
  ]
}